Inmune Stock News

XPro™ treatment shows statistically significant decrease in Phospho Tau 217 (pT271) and pT181, and an improvement in an imaging biomarker of myelination. XPro™ treatment shows statistically signif

First positive clinical confirmation of in vivo NK response, mirroring in vitro data

Our Bullish Take On INmune Bio's Drug Pipeline

BOCA RATON, Florida, Aug. 10, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the pat

INmune Bio, Inc. (INMB) CEO David Moss on Q2 2021 Results - Earnings Call Transcript

LA JOLLA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) --   INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the pat

Company to host conference call today, August 4, at 4:30pm ET Company to host conference call today, August 4, at 4:30pm ET

Phase 2 study of XPro TM will be a six -month , blinded , randomized , placebo-controlled trial in 168 patients with m ild A lzheimer's disease and biomarkers of inflammation .

AMSTERDAM, July 22, 2021 /PRNewswire/ -- LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, has

Company to introduce design of upcoming Phase 2 study of XPro1595 in Alzheimer's disease, which is expected to commence this year

INmune Bio Inc (NASDAQ: INMB) has announced a direct offering of 1.8 million shares at $22.00 per share for gross proceeds of approximately $40 million. The offering will close by July 16.

Boca Raton, FL., July 14, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that ha

With XPro1595, it has a disease-modifying drug candidate that has already shown to consistently decrease multiple biomarkers of neuroinflammation; The test is now how this affects biomarkers of neurod

The stock price of INmune Bio Inc (NASDAQ: INMB) increased by 10.64%. This is why it happened.

Purchase of Xencor Option potentially eliminates approximately 2.1  mill ion shares of INmune future common stock dilution upon execution.